Journal article

A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial

David W Johnson, Elaine M Pascoe, Sunil V Badve, Kim Dalziel, Alan Cass, Philip Clarke, Paolo Ferrari, Stephen P McDonald, Alicia T Morrish, Eugenie Pedagogos, Vlado Perkovic, Donna Reidlinger, Anish Scaria, Rowan Walker, Liza A Vergara, Carmel M Hawley

American Journal of Kidney Diseases | W B SAUNDERS CO-ELSEVIER INC | Published : 2015

Abstract

BACKGROUND: Erythropoiesis-stimulating agent (ESA)-hyporesponsive anemia is common in chronic kidney disease (CKD). Pentoxifylline shows promise as a treatment for ESA-hyporesponsive anemia, but has not been rigorously evaluated. STUDY DESIGN: Multicenter, double-blind, randomized, controlled trial. SETTING & PARTICIPANTS: 53 adult patients with CKD stage 4 or 5 (including dialysis) and ESA-hyporesponsive anemia (hemoglobin≤120g/L and ESA resistance index [calculated as weight-adjusted weekly ESA dose in IU/kg/wk divided by hemoglobin concentration in g/L]≥1.0IU/kg/wk/g/L for erythropoietin-treated patients and ≥0.005μg/kg/wk/g/L for darbepoetin-treated patients). INTERVENTIONS: Pentoxifylli..

View full abstract

Grants

Funding Acknowledgements

Dr Johnson has previously received consultancy fees from Sanofi-Aventis and consultancy fees, speakers' honoraria, research grants, and travel sponsorships from Amgen, Roche, and Janssen-Cilag. He was the recipient of a RoFAR grant, which partly funded the HERO trial, and a Queensland Government Health Research Fellowship. Dr Hawley has previously received consultancy fees, speakers' honoraria, research grants, and/or travel sponsorships from Amgen, Roche, and Janssen-Cilag. Dr Cass has previously received consultancy fees, speakers' honoraria, and/or research grants from Amgen, Roche, Baxter, Fresenius, and Merck. Dr Walker has previously received consultancy fees, speakers' honoraria, research grants, and travel sponsorships from Amgen, Roche, and Janssen-Cilag and has served on Advisory Boards for Amgen, Roche, and Janssen-Cilag. The other authors declare that they have no other relevant financial interests.